Pfizer Inc. (PFE) Announces FDA’s Grant of Priority Review for HYMPAVZI® (marstacimab) sBLA

Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients with hemophilia A or B without inhibitors. HYMPAVZI currently holds approval for the treatment of patients 12 years of age and older with hemophilia A without factor VIII inhibitors, or hemophilia B without factor IX inhibitors in the United States.

Pfizer Inc. (NYSE:PFE) further reported that the FDA set a Prescription Drug User Fee Act action date in Q2 2026. If approved, HYMPAVZI would provide a combination of bleed protection with a straightforward, once-weekly subcutaneous injection administration that requires minimal preparation without a need for routine treatment-related lab monitoring for these difficult-to-treat patient populations.

In another development, Pfizer Inc. (NYSE:PFE) announced on February 5 the launch of its program on TrumpRx to make innovative medicines more accessible and affordable for Americans. The program provides Americans with considerable discounts off list prices on over 30 medicines. Management reported that the initiative is a part of Pfizer Inc.’s (NYSE:PFE) broader landmark Most Favored Nation agreement with the U.S. government.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.